Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis

Published:2023-04 Issue: Volume:184 Page:103952
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Hassing Christina M.S.,Nielsen Dorte Lisbet,Knoop Ann Søegaard,Tvedskov Tove Holst Filtenborg,Kroman Niels,Lænkholm Anne-Vibeke,Juhl Carsten Bogh,Kümler Iben

Funder

Danish Cancer Society

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference48 articles.

1. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study;Ali;Sci. Rep.,2022

2. Detailed breast cancer pathology data for large-scale studies – access and completeness in NSW, Australia;Bartlett;Public Heal Res Pr.,2021

3. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials;Bradley;Lancet Oncol.,2021

4. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021;Burstein;Ann. Oncol.,2021

5. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial;Cameron;Lancet,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30